In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
A relevant aspect in the treatment of patients with hemophilia A (HA) presenting inhibitor against factor VIII (FVIII) is the different antigenicity of FVIII used for replacement therapy. The aim of the study was to assess the effect of different products, with variable von Willebrand factor (vWF) concentration, in preventing the binding of inhibitor to FVIII. The reactivity of inhibitors from plasma of 18 patients with HA versus three commercial concentrates containing different amounts of vWF was compared. The results show that increasing amounts of vWF might have a protective effect on the transfused FVIII inactivation.
Tagariello
Giuseppe
G
Haemophilia Centre and Regional Blood Disease Centre, Castelfranco Veneto Hospital, Azienda ULSS 8, Regione Veneto, Italy. gtagariello@ulssasolo.ven.it
Zanotto
Daniela
D
Radossi
Paolo
P
Sartori
Roberto
R
Belvini
Donata
D
Salviato
Roberta
R
D000328:Adult; D001688:Biological Products / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000276:immunology; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000737:chemistry* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics; D006467:Hemophilia A / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007223:Infant; D008875:Middle Aged; D009154:Mutation; D013997:Time Factors; D014841:von Willebrand Factor / Q000032:analysis / Q000737:chemistry*
D001688:Biological Products; D019774:Blood Coagulation Factor Inhibitors; D014841:von Willebrand Factor; D005169:Factor VIII